Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Purchases $95,890.00 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Amit Kumar purchased 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the acquisition, the chief executive officer now owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Anixa Biosciences Price Performance

NASDAQ ANIX opened at $2.41 on Friday. The stock has a market capitalization of $77.59 million, a price-to-earnings ratio of -6.18 and a beta of 0.90. Anixa Biosciences, Inc. has a 1-year low of $2.07 and a 1-year high of $5.13. The business’s fifty day moving average price is $2.80 and its 200-day moving average price is $3.02.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Equities research analysts anticipate that Anixa Biosciences, Inc. will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Concorde Asset Management LLC purchased a new position in shares of Anixa Biosciences in the second quarter worth approximately $31,000. Virtu Financial LLC bought a new position in Anixa Biosciences in the third quarter worth approximately $34,000. Westside Investment Management Inc. boosted its stake in shares of Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management grew its position in shares of Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the period. Finally, International Assets Investment Management LLC increased its stake in shares of Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares in the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Analyst Ratings Changes

ANIX has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.